Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression

被引：0
|
作者：
Abraham, Jame
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2014年 / 12卷 / 12期
关键词：
D O I：
10.12788/jcso.0093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：428 / 430
页数：3
相关论文
共 50 条
  • [31] Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs, Charles S.
    Tomasek, Jiri
    Yong, Cho Jae
    Dumitru, Filip
    Passalacqua, Rodolfo
    Goswami, Chanchal
    Safran, Howard
    dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David R.
    Melichar, Bohuslav
    Tehfe, Mustapha
    Topuzov, Eldar
    Zalcberg, John Raymond
    Chau, Ian
    Campbell, William
    Sivanandan, Choondal
    Pikiel, Joanna
    Koshiji, Minori
    Hsu, Yanzhi
    Liepa, Astra M.
    Gao, Ling
    Schwartz, Jonathan D.
    Tabernero, Josep
    [J]. LANCET, 2014, 383 (9911): : 31 - 39
  • [32] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Buyukkaramikli, Nasuh C.
    Blommestein, Hedwig M.
    Riemsma, Rob
    Armstrong, Nigel
    Clay, Fiona J.
    Ross, Janine
    Worthy, Gill
    Severens, Johan
    Kleijnen, Jos
    Al, Maiwenn J.
    [J]. PHARMACOECONOMICS, 2017, 35 (12) : 1211 - 1221
  • [33] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nasuh C. Büyükkaramikli
    Hedwig M. Blommestein
    Rob Riemsma
    Nigel Armstrong
    Fiona. J. Clay
    Janine Ross
    Gill Worthy
    Johan Severens
    Jos Kleijnen
    Maiwenn J. Al
    [J]. PharmacoEconomics, 2017, 35 : 1211 - 1221
  • [34] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.
    Al-Batran, Salah-Eddin
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Muro, Kei
    Liepa, Astra M.
    Ballal, Shaila
    Emig, Michael
    Ohtsu, Atsushi
    Wilke, Hansjochen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    Santana-Davila, Rafael
    Ahnert, Jordi Rodon
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Yang, Jing
    Rege, Jessicca
    Mi, Gu
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [36] Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)
    Cascinu, S.
    Aprile, G.
    Pastorelli, D.
    Pinto, C.
    Bordonaro, R.
    Farina, G.
    Amoroso, D.
    Bilancia, D.
    Ciuffreda, L.
    Sartori, D.
    Falcone, A.
    Silvestris, N.
    Beretta, G. D.
    Buonadonna, A.
    Sobrero, A.
    Tamburini, E.
    Amoroso, V.
    Hsu, Y.
    Chandrawansa, K.
    Wilke, H.
    Fuchs, C.
    Passalacqua, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 90 - 90
  • [37] Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Allen, Michael J.
    Suzuki, Chihiro
    Espin-Garcia, Osvaldo
    Ma, Lucy Xiaolu
    Honorio, Marta
    Lyra-Gonzalez, Ivan
    Chen, Eric Xueyu
    Darling, Gail Elizabeth
    Yeung, Jonathan
    Kalimuthu, Sangeetha
    Wong, Rebecca
    Veit-Haibach, Patrick
    Jang, Raymond Woo-Jun
    Elimova, Elena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial
    Leitner, H.
    [J]. TUMORBOARD, 2015, 4 (01): : 18 - 19
  • [39] Ramucirumab in Combination with Pembrolizumab in Treatment-Naive Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
    Chau, Ian
    Penel, Nicolas
    Soriano, Andres O.
    Arkenau, Hendrik-Tobias
    Cultrera, Jennifer
    Santana-Davila, Rafael
    Calvo, Emiliano
    Le Tourneau, Christophe
    Zender, Lars
    Bendell, Johanna C.
    Mi, Gu
    Gao, Ling
    McNeely, Samuel Clark
    Oliveira, Joana M.
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. CANCERS, 2020, 12 (10) : 1 - 16
  • [40] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Wilke, Hansjochen
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang-Cheul
    Bodoky, Gyoergy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Komatsu, Yoshito
    Ajani, Jaffer
    Emig, Michael
    Carlesi, Roberto
    Ferry, David
    Chandrawansa, Kumari
    Schwartz, Jonathan D.
    Ohtsu, Atsushi
    [J]. LANCET ONCOLOGY, 2014, 15 (11): : 1224 - 1235
12345